Caplyta is now FDA-approved for MDD treatment in adults, marking its fourth indication, including bipolar I and II depression ...
In today’s Pharmaceutical Executive Daily, we cover Novo Nordisk’s amended proposal to acquire Metsera, the State of Texas’ attempt to block Kenvue’s planned dividend payment, and how data and AI are ...
In today’s Pharmaceutical Executive Daily, we cover Kimberly-Clark’s $48.7 billion acquisition of Kenvue, Cencora’s $1 ...
Novo Nordisk’s amended proposal values Metsera at $86.20-per-share, for a total value upwards of $10 billion, representing an ...
Raj Indupuri, CEO, eClinical Solutions, touched on how AI can significantly enhance risk identification and mitigation in clinical trials by enabling integrated, data-driven quality management from ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback